Mark Loetzerich earned his PhD in molecular virology from the Ludwig Maximilian University Munich in Germany. With almost 20 years of work experience, he is an expert in the fields of both RNA- and DNA viruses & immunology. In Switzerland Mark worked at 3V Biosciences and specialized on virus-host interactions, cell death, and immune evasion mechanisms of respiratory viruses and possible countermeasures.

In the USA Mark lead a highly translational research project at the Hussman Institute in Baltimore linked to viral triggers of multiple sclerosis. Prior joining Cyagen he worked as director for infectious disease for the gene therapy program of UPenn in Philadelphia on a new biologic platform for the treatment of COVID-19 and to transfer this technology to other pandemic viral threads. Mark obtained a post-baccalaureate certificate in biochemical regulatory engineering from the UMBC and was decorated with the Hussman Meritorious Award.

Lucy is based in Boston and holds a B.S. in Biochemistry and Molecular Biology at the Wake Forest University. She earned her PhD in Biomolecular Pharmacology at Boston University, where she investigated how mRNA editing and posttranslational modifications influence glutamate receptor function and synaptic plasticity in sensory systems.

She now applying her scientific expertise to support drug-discovery partnerships and drive growth across the Northeast US market.